CALySSEY
Chimeric Antigen Receptor Treatment Targeting Lymphoma, Myeloma and Solid Tumors That Express CD70 (SEventY) CALySSEY
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1
- Enrollment
- 88 patients (estimated)
- Sponsors
- Baylor College of Medicine
- Collaborators
- Houston Methodist Hospital Research Institute
- Tags
- CAR T Cell, CD70
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2207
- NCT Identifier
- NCT07297160
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.